CoChat
Sign Up
Cited by 110Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkersvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Peptide-based vaccine for cancer therapies

Open access
Buonaguro, Luigi, Tagliamonte, Maria·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1210044PMC PMC10467431
Open this paper in CoChat — free accountOpen PDF

Abstract

Different strategies based on peptides are available for cancer treatment, in particular to counter-act the progression of tumor growth and disease relapse. In the last decade, in the context of therapeutic strategies against cancer, peptide-based vaccines have been evaluated in different tumor models. The peptides selected for cancer vaccine development can be classified in two main type: tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs), which are captured, internalized, processed and presented by antigen-presenting cells (APCs) to cell-mediated immunity. Peptides loaded onto MHC class I are recognized by a specific TCR of CD8+ T cells, which are activated to exert their cytotoxic activity against tumor cells presenting the same peptide-MHC-I complex. This process is defined as active immunotherapy as the host’s immune system is either de novo activated or restimulated to mount an effective, tumor-specific immune reaction that may ultimately lead to tu-mor regression. However, while the preclinical data have frequently shown encouraging results, therapeutic cancer vaccines clinical trials, including those based on peptides have not provided satisfactory data to date. The limited efficacy of peptide-based cancer vaccines is the consequence of several factors, including the identification of specific target tumor antigens, the limited immunogenicity of peptides and the highly immunosuppressive tumor microenvironment (TME). An effective cancer vaccine can be developed only by addressing all such different aspects. The present review describes the state of the art for each of such factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1210044

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 209

  1. van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 10.1126/science.1840703 · DOI
  2. Henderson, 1996, Human tumor antigens are ready to fly, Adv Immunol, 62, 10.1016/s0065-2776(08)60431-9 · DOI
  3. Graziano, 2005, Tumor antigens and tumor antigen discovery, Cancer Treat Res, 123, 89, 10.1007/0-387-27545-2_4 · DOI
  4. Vonderheide, 1999, The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes, Immunity, 10, 10.1016/s1074-7613(00)80066-7 · DOI
  5. Disis, 2009, Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer, J Clin Oncol, 27, 10.1200/JCO.2008.20.6789 · DOI
  6. Finn, 2011, Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas, Immunol Res, 50, 10.1007/s12026-011-8214-1 · DOI
  7. Parkhurst, 1998, Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2), Cancer Res, 58
  8. Correale, 1997, In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen, J Natl Cancer Inst, 89, 293, 10.1093/jnci/89.4.293 · DOI
  9. Hofmann, 2008, Genome-wide analysis of cancer/testis gene expression, Proc Natl Acad Sci U.S.A., 105, 10.1073/pnas.0810777105 · DOI
  10. Hollingsworth, 2019, Turning the corner on therapeutic cancer vaccines, NPJ Vaccines, 4, 7, 10.1038/s41541-019-0103-y · DOI · Paper page
  11. Vigneron, 2015, Human tumor antigens and cancer immunotherapy, BioMed Res Int, 2015, 10.1155/2015/948501 · DOI
  12. Tagliamonte, 2014, Antigen-specific vaccines for cancer treatment, Hum Vaccin Immunother, 10, 10.4161/21645515.2014.973317 · DOI
  13. Schumacher, 2019, Cancer neoantigens, Annu Rev Immunol, 37, 173, 10.1146/annurev-immunol-042617-053402 · DOI
  14. Hoebe, 2004, The interface between innate and adaptive immunity, Nat Immunol, 5, 10.1038/ni1004-971 · DOI
  15. Halle, 2017, Mechanisms and dynamics of T cell-mediated cytotoxicity in Vivo, Trends Immunol, 38, 10.1016/j.it.2017.04.002 · DOI · Paper page
  16. Pulendran, 2021, Emerging concepts in the science of vaccine adjuvants, Nat Rev Drug Discovery, 20, 10.1038/s41573-021-00163-y · DOI
  17. Melero, 2014, Therapeutic vaccines for cancer: an overview of clinical trials, Nat Rev Clin Oncol, 11, 10.1038/nrclinonc.2014.111 · DOI
  18. Melief, 2015, Therapeutic cancer vaccines, J Clin Invest, 125, 10.1172/JCI80009 · DOI
  19. Goydos, 1996, A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma, J Surg Res, 63, 298, 10.1006/jsre.1996.0264 · DOI
  20. Apostolopoulos, 2013, Targeting antigens to dendritic cell receptors for vaccine development, J Drug Delivery, 2013, 10.1155/2013/869718 · DOI
  21. Sheng, 2006, Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells, Immunology, 118, 10.1111/j.1365-2567.2006.02384.x · DOI
  22. Apostolopoulos, 2015, MUC1 (CD227): a multi-tasked molecule, Cell Mol Life Sci, 72, 10.1007/s00018-015-2014-z · DOI · Paper page
  23. Tang, 2008, Strategies used for MUC1 immunotherapy: human clinical studies, Expert Rev Vaccines, 7, 10.1586/14760584.7.7.963 · DOI
  24. Tang, 2008, Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses, Vaccine, 26, 10.1016/j.vaccine.2008.05.008 · DOI
  25. Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin Cancer Res, 15, 10.1158/1078-0432.CCR-09-0737 · DOI
  26. Hossain, 2016, Immunological evaluation of recent MUC1 glycopeptide cancer vaccines, Vaccines (Basel), 4, 10.3390/vaccines4030025 · DOI · Paper page
  27. Hollingsworth, 2004, Mucins in cancer: protection and control of the cell surface, Nat Rev Cancer, 4, 45, 10.1038/nrc1251 · DOI
  28. Kimura, 2013, MUC1 immunotherapy is here to stay, Expert Opin Biol Ther, 13, 35, 10.1517/14712598.2012.725719 · DOI
  29. Rajabi, 2017, MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas, Biochim Biophys Acta Rev Cancer, 1868, 10.1016/j.bbcan.2017.03.003 · DOI
  30. Bouillez, 2017, MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer, Oncogene, 36, 10.1038/onc.2017.47 · DOI
  31. Bouillez, 2017, MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer, Oncoimmunology, 6, 10.1080/2162402X.2017.1338998 · DOI
  32. Gulley, 2014, Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer, Cancer Immunol Res, 2, 10.1158/2326-6066.CIR-13-0108 · DOI
  33. Arlen, 2007, Clinical safety of a viral vector based prostate cancer vaccine strategy, J Urol, 178, 10.1016/j.juro.2007.05.117 · DOI
  34. Hatziioannou, 2017, Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force, J Leukoc Biol, 102, 10.1189/jlb.5VMR1116-493R · DOI
  35. Campoli, 2008, HLA antigen changes in Malignant cells: epigenetic mechanisms and biologic significance, Oncogene, 27, 10.1038/onc.2008.273 · DOI
  36. Godfrey, 2018, Unconventional T cell targets for cancer immunotherapy, Immunity, 48, 10.1016/j.immuni.2018.03.009 · DOI
  37. Petrizzo, 2018, Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting, Oncotarget, 9, 10.18632/oncotarget.23181 · DOI
  38. Lee, 2021, Combination therapies utilizing neoepitope-targeted vaccines, Cancer Immunol Immunother, 70, 10.1007/s00262-020-02729-y · DOI
  39. Kerr, 2021, Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer, Expert Opin Drug Discovery, 16, 89, 10.1080/17460441.2020.1811673 · DOI
  40. Garboczi, 1996, Structure of the complex between human T-cell receptor, viral peptide and HLA-A2, Nature, 384, 10.1038/384134a0 · DOI
  41. Rammensee, 1995, MHC ligands and peptide motifs: first listing, Immunogenetics, 41, 178, 10.1007/bf00172063 · DOI
  42. Bijker, 2008, Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation, Eur J Immunol, 38, 10.1002/eji.200737995 · DOI
  43. Sidney, 1995, Several HLA alleles share overlapping peptide specificities, J Immunol, 154, 10.4049/jimmunol.154.1.247 · DOI
  44. Southwood, 1998, Several common HLA-DR types share largely overlapping peptide binding repertoires, J Immunol, 160, 10.4049/jimmunol.160.7.3363 · DOI
  45. Diao, 2013, Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides, Clin Pharmacokinet, 52, 10.1007/s40262-013-0079-0 · DOI
  46. Di, 2015, Addressing the challenges of low clearance in drug research, AAPS J, 17, 10.1208/s12248-014-9691-7 · DOI
  47. Falk, 1991, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 10.1038/351290a0 · DOI
  48. Walter, 2012, Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nat Med, 18, 10.1038/nm.2883 · DOI
  49. Feyerabend, 2009, Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer, Prostate, 69, 10.1002/pros.20941 · DOI
  50. Löffler, 2022, Phase I/II multicenter trial of a novel therapeutic cancer vaccine, hepaVac-101, for hepatocellular carcinoma, Clin Cancer Res, 28, 10.1158/1078-0432.Ccr-21-4424 · DOI
  51. Hung, 1998, The central role of CD4(+) T cells in the antitumor immune response, J Exp Med, 188, 10.1084/jem.188.12.2357 · DOI · Paper page
  52. Matsui, 1999, A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL, J Immunol, 163, 10.4049/jimmunol.163.1.184 · DOI
  53. Pardoll, 1999, Inducing autoimmune disease to treat cancer, Proc Natl Acad Sci U.S.A., 96, 10.1073/pnas.96.10.5340 · DOI
  54. Ciesielski, 2010, Antitumor cytotoxic T-cell response induced by a survivin peptide mimic, Cancer Immunol Immunother, 59, 10.1007/s00262-010-0845-x · DOI
  55. Ciesielski, 2008, Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma, Cancer Immunol Immunother, 57, 10.1007/s00262-008-0510-9 · DOI
  56. Kenter, 2009, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N Engl J Med, 361, 10.1056/NEJMoa0810097 · DOI
  57. van Poelgeest, 2016, Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: Lesion clearance is related to the strength of the T-cell response, Clin Cancer Res, 22, 10.1158/1078-0432.CCR-15-2594 · DOI
  58. Massarelli, 2019, Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial, JAMA Oncol, 5, 67, 10.1001/jamaoncol.2018.4051 · DOI · Paper page
  59. Pavlick, 2020, Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma, Cancer Immunol Res, 8, 70, 10.1158/2326-6066.Cir-19-0545 · DOI
  60. Comiskey, 2018, Immunotherapy in prostate cancer: Teaching an old dog new tricks, Curr Oncol Rep, 20, 75, 10.1007/s11912-018-0712-z · DOI
  61. Buonaguro, 2020, Selecting target antigens for cancer vaccine development, Vaccines (Basel), 8, 10.3390/vaccines8040615 · DOI
  62. Karbach, 2011, Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients, Clin Cancer Res, 17, 10.1158/1078-0432.Ccr-10-1811 · DOI
  63. Buonaguro, 2011, Translating tumor antigens into cancer vaccines, Clin Vaccine Immunol, 18, 23, 10.1128/cvi.00286-10 · DOI
  64. Roudko, 2020, Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors, Cell, 183, 1634, 10.1016/j.cell.2020.11.004 · DOI
  65. Smith, 2019, Alternative tumour-specific antigens, Nat Rev Cancer, 19, 10.1038/s41568-019-0162-4 · DOI
  66. Engelhard, 2020, MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma, J Immunother Cancer, 8, 10.1136/jitc-2019-000262 · DOI
  67. Malaker, 2017, Identification of glycopeptides as posttranslationally modified neoantigens in leukemia, Cancer Immunol Res, 5, 10.1158/2326-6066.Cir-16-0280 · DOI
  68. Gubin, 2015, Tumor neoantigens: building a framework for personalized cancer immunotherapy, J Clin Invest, 125, 10.1172/jci80008 · DOI
  69. Hu, 2018, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat Rev Immunol, 18, 10.1038/nri.2017.131 · DOI · Paper page
  70. Sturm, 2021, Mild acid elution and MHC immunoaffinity chromatography reveal similar albeit not identical profiles of the HLA class I immunopeptidome, J Proteome Res, 20, 289, 10.1021/acs.jproteome.0c00386 · DOI
  71. Bassani-Sternberg, 2010, Soluble plasma HLA peptidome as a potential source for cancer biomarkers, Proc Natl Acad Sci U.S.A., 107, 10.1073/pnas.1008501107 · DOI
  72. Kessler, 2020, The potential of soluble human leukocyte antigen molecules for early cancer detection and therapeutic vaccine design, Vaccines (Basel), 8, 10.3390/vaccines8040775 · DOI
  73. Weinschenk, 2002, Integrated functional genomics approach for the design of patient-individual antitumor vaccines, Cancer Res, 62
  74. Singh-Jasuja, 2004, The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy, Cancer Immunol Immunother, 53, 10.1007/s00262-003-0480-x · DOI
  75. Rammensee, 2002, Towards patient-specific tumor antigen selection for vaccination, Immunol Rev, 188, 10.1034/j.1600-065x.2002.18815.x · DOI
  76. Rammensee, 1993, Peptides naturally presented by MHC class I molecules, Annu Rev Immunol, 11, 10.1146/annurev.iy.11.040193.001241 · DOI
  77. Kowalewski, 2013, Biochemical large-scale identification of MHC class I ligands, Methods Mol Biol, 960, 10.1007/978-1-62703-218-6_12 · DOI
  78. Nelde, 2019, Purification and identification of naturally presented MHC class I and II ligands, Methods Mol Biol, 1988, 10.1007/978-1-4939-9450-2_10 · DOI
  79. Bichmann, 2019, MHCquant: Automated and reproducible data analysis for immunopeptidomics, J Proteome Res, 18, 10.1021/acs.jproteome.9b00313 · DOI
  80. Pak, 2021, Sensitive immunopeptidomics by leveraging available large-scale multi-HLA spectral libraries, data-independent acquisition, and MS/MS prediction, Mol Cell Proteomics, 20, 10.1016/j.mcpro.2021.100080 · DOI
  81. Ghosh, 2020, Guidance document: Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for pharmaceutical therapies, Mol Cell Proteomics, 19, 10.1074/mcp.C119.001652 · DOI
  82. Erhard, 2020, Identification of the cryptic HLA-I immunopeptidome, Cancer Immunol Res, 8, 10.1158/2326-6066.Cir-19-0886 · DOI
  83. Erhard, 2018, Improved Ribo-seq enables identification of cryptic translation events, Nat Methods, 15, 10.1038/nmeth.4631 · DOI
  84. Laumont, 2018, Noncoding regions are the main source of targetable tumor-specific antigens, Sci Transl Med, 10, 10.1126/scitranslmed.aau5516 · DOI
  85. Creech, 2018, The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction, Proteomics, 18, 10.1002/pmic.201700259 · DOI
  86. Laumont, 2018, Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy, Cell Mol Life Sci, 75, 10.1007/s00018-017-2628-4 · DOI
  87. Peters, 2020, T cell epitope predictions, Annu Rev Immunol, 38, 10.1146/annurev-immunol-082119-124838 · DOI
  88. Bassani-Sternberg, 2016, Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry, Nat Commun, 7, 10.1038/ncomms13404 · DOI · Paper page
  89. Löffler, 2019, Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma, Genome Med, 11, 28, 10.1186/s13073-019-0636-8 · DOI
  90. Mauriello, 2019, High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients not undergoing immunotherapy, Cancers (Basel), 11, 10.3390/cancers11121824 · DOI
  91. Petrizzo, 2018, Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients, J Transl Med, 16, 286, 10.1186/s12967-018-1662-9 · DOI
  92. Raoufi, 2020, Epitope prediction by novel immunoinformatics approach: A state-of-the-art review, Int J Pept Res Ther, 26, 10.1007/s10989-019-09918-z · DOI
  93. Atanasova, 2013, EpiDOCK: a molecular docking-based tool for MHC class II binding prediction, Protein Eng Des Sel, 26, 10.1093/protein/gzt018 · DOI
  94. He, 2010, Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development, J BioMed Biotechnol, 2010, 10.1155/2010/297505 · DOI
  95. Molero-Abraham, 2013, Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses, Clin Dev Immunol, 2013, 10.1155/2013/601943 · DOI
  96. Doytchinova, 2006, EpiJen: a server for multistep T cell epitope prediction, BMC Bioinf, 7, 10.1186/1471-2105-7-131 · DOI
  97. Singh, 2001, ProPred: prediction of HLA-DR binding sites, Bioinformatics, 17, 10.1093/bioinformatics/17.12.1236 · DOI
  98. Larsen, 2005, An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions, Eur J Immunol, 35, 10.1002/eji.200425811 · DOI
  99. Zhang, 2011, Machine learning competition in immunology - Prediction of HLA class I binding peptides, J Immunol Methods, 374, 1, 10.1016/j.jim.2011.09.010 · DOI
  100. Dhanda, 2013, Prediction of IL4 inducing peptides, Clin Dev Immunol, 2013, 10.1155/2013/263952 · DOI
  101. Bhasin, 2004, SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence, Bioinformatics, 20, 10.1093/bioinformatics/btg424 · DOI
  102. Wang, 2008, A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach, PloS Comput Biol, 4, 10.1371/journal.pcbi.1000048 · DOI
  103. Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res, 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
  104. Sarkizova, 2020, A large peptidome dataset improves HLA class I epitope prediction across most of the human population, Nat Biotechnol, 38, 199, 10.1038/s41587-019-0322-9 · DOI
  105. Shao, 2020, High-throughput prediction of MHC class I and II neoantigens with MHCnuggets, Cancer Immunol Res, 8, 396, 10.1158/2326-6066.Cir-19-0464 · DOI
  106. Gfeller, 2016, Current tools for predicting cancer-specific T cell immunity, Oncoimmunology, 5, 10.1080/2162402x.2016.1177691 · DOI
  107. Juncker, 2009, Systematic characterisation of cellular localisation and expression profiles of proteins containing MHC ligands, PloS One, 4, 10.1371/journal.pone.0007448 · DOI
  108. Hickman, 2004, Toward a definition of self: proteomic evaluation of the class I peptide repertoire, J Immunol, 172, 10.4049/jimmunol.172.5.2944 · DOI
  109. Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 10.1016/j.immuni.2017.02.007 · DOI
  110. Fortier, 2008, The MHC class I peptide repertoire is molded by the transcriptome, J Exp Med, 205, 595, 10.1084/jem.20071985 · DOI
  111. Bassani-Sternberg, 2015, Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation, Mol Cell Proteomics, 14, 10.1074/mcp.M114.042812 · DOI
  112. Koşaloğlu-Yalçın, 2022, Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions, iScience, 25, 10.1016/j.isci.2022.103850 · DOI
  113. Toes, 1996, Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors, J Immunol, 156, 10.4049/jimmunol.156.10.3911 · DOI
  114. Tuettenberg, 2006, Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients, Int J Cancer, 118, 10.1002/ijc.21679 · DOI
  115. Bonam, 2017, An overview of novel adjuvants designed for improving vaccine efficacy, Trends Pharmacol Sci, 38, 10.1016/j.tips.2017.06.002 · DOI
  116. Dubensky, 2010, Adjuvants for cancer vaccines, Semin Immunol, 22, 10.1016/j.smim.2010.04.007 · DOI
  117. Temizoz, 2018, Combination and inducible adjuvants targeting nucleic acid sensors, Curr Opin Pharmacol, 41, 10.1016/j.coph.2018.05.003 · DOI
  118. Hogenesch, 2012, Mechanism of immunopotentiation and safety of aluminum adjuvants, Front Immunol, 3, 10.3389/fimmu.2012.00406 · DOI · Paper page
  119. Mosca, 2008, Molecular and cellular signatures of human vaccine adjuvants, Proc Natl Acad Sci U.S.A., 105, 10.1073/pnas.0804699105 · DOI
  120. Cuzzubbo, 2020, Cancer vaccines: Adjuvant potency, importance of age, lifestyle, and treatments, Front Immunol, 11, 10.3389/fimmu.2020.615240 · DOI
  121. Smith, 2018, Trial Watch: Toll-like receptor agonists in cancer immunotherapy, Oncoimmunology, 7, 10.1080/2162402x.2018.1526250 · DOI
  122. Gay, 2007, Structure and function of Toll receptors and their ligands, Annu Rev Biochem, 76, 10.1146/annurev.biochem.76.060305.151318 · DOI
  123. Takeda, 2003, Toll-like receptors, Annu Rev Immunol, 21, 10.1146/annurev.immunol.21.120601.141126 · DOI · Paper page
  124. Circelli, 2017, Immunological effects of a novel RNA-based adjuvant in liver cancer patients, Cancer Immunol Immunother, 66, 10.1007/s00262-016-1923-5 · DOI
  125. Smith, 2016, Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants, Vaccine, 34, 10.1016/j.vaccine.2016.06.080 · DOI
  126. Vollmer, 2009, Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists, Adv Drug Delivery Rev, 61, 195, 10.1016/j.addr.2008.12.008 · DOI
  127. Bode, 2011, CpG DNA as a vaccine adjuvant, Expert Rev Vaccines, 10, 499, 10.1586/erv.10.174 · DOI
  128. Martins, 2015, Vaccine adjuvant uses of poly-IC and derivatives, Expert Rev Vaccines, 14, 10.1586/14760584.2015.966085 · DOI
  129. Kyi, 2018, Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: A pilot trial, Clin Cancer Res, 24, 10.1158/1078-0432.Ccr-17-1866 · DOI
  130. Heidenreich, 2015, A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile, Int J Cancer, 137, 10.1002/ijc.29402 · DOI
  131. Krutzik, 2005, TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells, Nat Med, 11, 10.1038/nm1246 · DOI
  132. Jackson, 2018, Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults, Vaccine, 36, 10.1016/j.vaccine.2017.12.038 · DOI · Paper page
  133. Stark, 2008, Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation, Eur J Pharm Biopharm, 70, 10.1016/j.ejpb.2008.04.015 · DOI
  134. Arbelaez, 2020, A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses, NPJ Vaccines, 5, 106, 10.1038/s41541-020-00253-9 · DOI
  135. Chatin, 2015, Liposome-based formulation for intracellular delivery of functional proteins, Mol Ther Nucleic Acids, 4, 10.1038/mtna.2015.17 · DOI
  136. Varypataki, 2016, Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles, J Control Release, 226, 98, 10.1016/j.jconrel.2016.02.018 · DOI
  137. Petrizzo, 2015, Functional characterization of biodegradable nanoparticles as antigen delivery system, J Exp Clin Cancer Res, 34, 114, 10.1186/s13046-015-0231-9 · DOI
  138. Biswas, 2014, Nanopreparations for organelle-specific delivery in cancer, Adv Drug Delivery Rev, 66, 26, 10.1016/j.addr.2013.11.004 · DOI
  139. Koshy, 2016, Biomaterials for enhancing anti-cancer immunity, Curr Opin Biotechnol, 40, 1, 10.1016/j.copbio.2016.02.001 · DOI
  140. Fujita, 2011, Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles, Chem Cent J, 5, 10.1186/1752-153X-5-48 · DOI
  141. Grippin, 2017, Translational nanoparticle engineering for cancer vaccines, Oncoimmunology, 6, 10.1080/2162402X.2017.1290036 · DOI
  142. Lopez-Campos, 2019, Nanoparticles applied to cancer immunoregulation, Rep Pract Oncol Radiother, 24, 47, 10.1016/j.rpor.2018.10.001 · DOI
  143. Gao, 2019, Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy, Theranostics, 9, 10.7150/thno.29431 · DOI
  144. Butts, 2011, Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial, J Cancer Res Clin Oncol, 137, 10.1007/s00432-011-1003-3 · DOI
  145. Butts, 2010, A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer, Clin Lung Cancer, 11, 10.3816/CLC.2010.n.101 · DOI
  146. McQuade, 2018, A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma, BMC Cancer, 18, 1274, 10.1186/s12885-018-5193-9 · DOI
  147. Karkada, 2014, Therapeutic vaccines and cancer: focus on DPX-0907, Biologics, 8, 27, 10.2147/BTT.S55196 · DOI
  148. Klein, 2015, Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma, Cancer Immunol Immunother, 64, 10.1007/s00262-015-1656-x · DOI
  149. Kitano, 2006, HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan, Clin Cancer Res, 12, 10.1158/1078-0432.CCR-06-1546 · DOI
  150. Harari, 2020, Antitumour dendritic cell vaccination in a priming and boosting approach, Nat Rev Drug Discovery, 19, 10.1038/s41573-020-0074-8 · DOI
  151. Zitvogel, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat Med, 4, 594, 10.1038/nm0598-594 · DOI
  152. Seo, 2018, Exosome-mediated regulation of tumor immunology, Cancer Sci, 109, 2998, 10.1111/cas.13735 · DOI
  153. Munich, 2012, Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands, Oncoimmunology, 1, 10.4161/onci.20897 · DOI
  154. Pitt, 2016, Dendritic cell-derived exosomes for cancer therapy, J Clin Invest, 126, 10.1172/JCI81137 · DOI · Paper page
  155. Andre, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J Immunol, 172, 10.4049/jimmunol.172.4.2126 · DOI · Paper page
  156. Viaud, 2010, Dendritic cell-derived exosomes for cancer immunotherapy: what's next, Cancer Res, 70, 10.1158/0008-5472.CAN-09-3276 · DOI
  157. Wolfers, 2001, Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming, Nat Med, 7, 297, 10.1038/85438 · DOI
  158. Stuge, 2004, Diversity and recognition efficiency of T cell responses to cancer, PloS Med, 1, 10.1371/journal.pmed.0010028 · DOI
  159. Boon, 1989, T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions, A hypothesis Immunogenetics, 29, 10.1007/bf00395854 · DOI
  160. Fikes, 2003, Design of multi-epitope, analogue-based cancer vaccines, Expert Opin Biol Ther, 3, 10.1517/14712598.3.6.985 · DOI
  161. Kanaseki, 2019, Proteogenomics: advances in cancer antigen research, Immunol Med, 42, 65, 10.1080/25785826.2019.1640500 · DOI
  162. Carrabba, 2003, Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues, Cancer Res, 63
  163. Parkhurst, 1996, Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues, J Immunol, 157, 10.4049/jimmunol.157.6.2539 · DOI
  164. Madura, 2015, Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides, Eur J Immunol, 45, 10.1002/eji.201445114 · DOI
  165. Cavalluzzo, 2021, Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy, J Transl Med, 19, 89, 10.1186/s12967-021-02757-x · DOI
  166. Tagliamonte, 2021, MHC-optimized peptide scaffold for improved antigen presentation and anti-tumor response, Front Immunol, 12, 10.3389/fimmu.2021.769799 · DOI
  167. Wooldridge, 2012, A single autoimmune T cell receptor recognizes more than a million different peptides, J Biol Chem, 287, 10.1074/jbc.M111.289488 · DOI
  168. Sewell, 2012, Why must T cells be cross-reactive, Nat Rev Immunol, 12, 10.1038/nri3279 · DOI
  169. Ragone, 2021, Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs), J Immunother Cancer, 9, 10.1136/jitc-2021-002694 · DOI
  170. Vujanovic, 2014, Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses, Oncoimmunology, 3, 10.4161/21624011.2014.954501 · DOI
  171. Loftus, 1996, Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35), J Exp Med, 184, 10.1084/jem.184.2.647 · DOI
  172. Chiaro, 2021, Viral molecular mimicry influences the antitumor immune response in murine and human melanoma, Cancer Immunol Res, 9, 10.1158/2326-6066.Cir-20-0814 · DOI
  173. Tagliamonte, 2023, Molecular mimicry and cancer vaccine development, Mol Cancer, 22, 75, 10.1186/s12943-023-01776-0 · DOI
  174. Buonaguro, 2023, Microorganisms-derived antigens for preventive anti-cancer vaccines, Mol Aspects Med, 92, 10.1016/j.mam.2023.101192 · DOI
  175. Ragone, 2022, Molecular mimicry between tumor associated antigens and microbiota-derived epitopes, J Transl Med, 20, 316, 10.1186/s12967-022-03512-6 · DOI
  176. Buonaguro, 2021, Pathogens: Our allies against cancer, Mol Ther, 29, 10.1016/j.ymthe.2020.12.005 · DOI
  177. van der Burg, 2016, Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nat Rev Cancer, 16, 10.1038/nrc.2016.16 · DOI
  178. Saxena, 2021, Therapeutic cancer vaccines, Nat Rev Cancer, 21, 10.1038/s41568-021-00346-0 · DOI · Paper page
  179. Tagliamonte, 2018, Potentiating cancer vaccine efficacy in liver cancer, Oncoimmunology, 7, 10.1080/2162402X.2018.1488564 · DOI
  180. Chakraborty, 2004, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing, Cancer Res, 64, 10.1158/0008-5472.Can-04-0073 · DOI
  181. Gameiro, 2016, Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing, Int J Radiat Oncol Biol Phys, 95, 10.1016/j.ijrobp.2016.02.022 · DOI
  182. Hodge, 2013, Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death, Int J Cancer, 133, 10.1002/ijc.28070 · DOI
  183. Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, 56, 10.1007/s00262-006-0225-8 · DOI
  184. Suzuki, 2005, Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clin Cancer Res, 11, 10.1158/1078-0432.Ccr-05-0883 · DOI · Paper page
  185. Garnett, 2008, Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement, Clin Cancer Res, 14, 10.1158/1078-0432.Ccr-07-4025 · DOI
  186. Tagliamonte, 2016, A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice, J Transl Med, 14, 58, 10.1186/s12967-016-0812-1 · DOI
  187. Tagliamonte, 2015, Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model, Cancer Immunol Immunother, 64, 10.1007/s00262-015-1698-0 · DOI
  188. Madondo, 2016, Low dose cyclophosphamide: Mechanisms of T cell modulation, Cancer Treat Rev, 42, 3, 10.1016/j.ctrv.2015.11.005 · DOI
  189. Rampling, 2016, A cancer research UK first time in human phase I trial of IMA950 (Novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma, Clin Cancer Res, 22, 10.1158/1078-0432.Ccr-16-0506 · DOI
  190. Demaria, 2015, Role of local radiation therapy in cancer immunotherapy, JAMA Oncol, 1, 10.1001/jamaoncol.2015.2756 · DOI
  191. Dillon, 2019, ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment, Clin Cancer Res, 25, 10.1158/1078-0432.Ccr-18-1821 · DOI
  192. Weichselbaum, 2017, Radiotherapy and immunotherapy: a beneficial liaison, Nat Rev Clin Oncol, 14, 10.1038/nrclinonc.2016.211 · DOI
  193. Stamell, 2013, The abscopal effect associated with a systemic anti-melanoma immune response, Int J Radiat Oncol Biol Phys, 85, 10.1016/j.ijrobp.2012.03.017 · DOI
  194. Golden, 2013, An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer, Cancer Immunol Res, 1, 10.1158/2326-6066.Cir-13-0115 · DOI
  195. Chandra, 2015, A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab, Oncoimmunology, 4, 10.1080/2162402x.2015.1046028 · DOI
  196. Kulzer, 2014, Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells, J Immunotoxicol, 11, 10.3109/1547691x.2014.880533 · DOI
  197. Mondini, 2015, Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer, Mol Cancer Ther, 14, 10.1158/1535-7163.Mct-14-1015 · DOI
  198. Chang, 2018, Irradiation enhances abscopal anti-tumor effects of antigen-specific immunotherapy through regulating tumor microenvironment, Mol Ther, 26, 10.1016/j.ymthe.2017.11.011 · DOI
  199. Sharma, 2023, Immune checkpoint therapy-current perspectives and future directions, Cell, 186, 10.1016/j.cell.2023.03.006 · DOI · Paper page
  200. Nasti, 2021, Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy, Vaccines (Basel), 9, 10.3390/vaccines9121396 · DOI

200 of 209 shown

Metadata

Authors
Buonaguro, L., & Tagliamonte, M.
Affiliations
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Corresponding author
Tagliamonte, Maria
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-08-16
Volume
14
Pages
1210044-1210044
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2023.1210044
PMC
PMC10467431
OpenAlex
W4385954728
Cited by
110
References
11
Citations by year
2026: 24 · 2025: 50 · 2024: 33 · 2023: 3
FWCI
2.73
Type
journal article
Language
en
Update notices
corrigendum (2023-10-26)
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
Funders
Ministero della Salute
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
peptide vaccine, cancer immunotherapy, tumor-associated antigens, tumor-specific antigens, MHC class I, CD8+ T cells, antigen-presenting cells, tumor microenvironment, immunosuppression, tumor regression
MeSH terms
Antigen-Presenting Cells, Genes, MHC Class I, Immunity, Cellular, Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review